Cure

WAKE RADIOLOGY SUPPORTS TRIANGLE RACE FOR THE CURE WITH THIRD LARGEST TEAM, $11,100 CONTRIBUTION

Retrieved on: 
Mardi, mai 7, 2024
Cancer, Cure, Mammography, Woman, Breast cancer, Radiology, Triangle Park (Quezon City), Research, Survivor, Disease, Patient, Triangle, Star Wars Day

RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Wake Radiology UNC REX Healthcare, the oldest and largest outpatient imaging provider in the Triangle, contributed $11,100 to breast cancer research as a Gold Sponsor of the 2024 Komen Triangle Race for the Cure, held Saturday, May 4, at Boxyard RTP in Research Triangle Park.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Wake Radiology UNC REX Healthcare, the oldest and largest outpatient imaging provider in the Triangle, contributed $11,100 to breast cancer research as a Gold Sponsor of the 2024 Komen Triangle Race for the Cure, held Saturday, May 4, at Boxyard RTP in Research Triangle Park.
  • This year, more than 50 members of the Wake Radiology team participated in the 5K race, two of whom are breast cancer survivors.
  • As an added incentive to schedule an exam, Wake Radiology offered race participants and spectators a chance to enter to win four on-site giveaways.
  • For more information, or to make a gift in support of breast cancer research and patients, please visit https://www.komen.org/how-to-help/attend-events/race-for-the-cure/ .

Timeless Vapes Partners with DJ Stewart to Continue the Fight Against Brain Cancer

Retrieved on: 
Mardi, mai 7, 2024
Timeless, Cancer, Cure, Marketing, Love, Partnership, Cannabis, Brain, DJ Stewart

SCOTTSDALE, Ariz., May 7, 2024 /PRNewswire/ -- Timeless Vapes ("Timeless" or the "Company"), a lifestyle brand leading the way in cannabis culture, today announced its partnership with brain cancer survivor DJ Stewart for the second annual Shred for the Cure campaign, an initiative to benefit the Head for the Cure Foundation, a nonprofit dedicated to raising awareness and funding in the battle against brain cancer.

Key Points: 
  • DJ Stewart is a skateboarder and cannabis advocate from Kansas City dedicated to raising awareness for brain cancer and the impact cannabis had in his healing journey.
  • In 2023, Timeless partnered with Stewart and Kansas City artist John F. Malta on Shred for the Cure's inaugural campaign in Missouri, which raised $13,000 for Head for the Cure.
  • "I've been so fortunate to meet and work with DJ Stewart on this campaign," said Kyle Webb, VP of Marketing at Timeless.
  • To celebrate the campaign with their communities, Timeless and DJ Stewart will host the "Shred for the Cure Skate Jam" in Kansas City on Saturday, May 18th.

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

Retrieved on: 
Mercredi, avril 24, 2024
Cure, Safety, Tumor microenvironment, Intelligence, PDAC, ASCO, Merck & Co., Society, Poster, Annual general meeting, Therapy, Merck, Pharmaceutical industry

NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that a late-breaking abstract with preliminary findings from the Phase 2 investigator-sponsored trial of BXCL701 in combination with KEYTRUDA® (pembrolizumab) in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) has been selected for presentation in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place from May 31 to June 4, 2024 in Chicago, IL.

Key Points: 
  • The meeting will take place from May 31 to June 4, 2024 in Chicago, IL.
  • On February 6, 2024, BioXcel Therapeutics announced the completion of patient enrollment in the safety lead-in portion of the trial.
  • Through its OnkosXcel Therapeutics immuno-oncology subsidiary, BioXcel Therapeutics is collaborating with Dr. Louis M. Weiner, director of the Lombardi Comprehensive Cancer Center, and Dr. Benjamin Weinberg, principal investigator of the study.
  • BioXcel Therapeutics and Merck & Co. are providing BXCL701 and KEYTRUDA for the trial, respectively.

Painting Homes, Changing Lives: Fresh Coat Painters of Tampa Provides Pro Bono Bedroom Painting for Pediatric Cancer Patients with the National Pediatric Cancer Foundation

Retrieved on: 
Mercredi, avril 17, 2024
Philanthropy, Family, Oncology, Consumer, Other Construction & Property, Residential Building & Real Estate, Construction & Property, Foundation, Children, Urban Planning, Other Philanthropy, Health, Interior Design, Environment, Antonella, Cure, Partnership, Patient, Research, Nursing

Fresh Coat Painters of Tampa , in collaboration with the National Pediatric Cancer Foundation (NPCF) , is proud to announce a heartwarming initiative aimed at bringing joy and comfort to pediatric cancer patients and their families.

Key Points: 
  • Fresh Coat Painters of Tampa , in collaboration with the National Pediatric Cancer Foundation (NPCF) , is proud to announce a heartwarming initiative aimed at bringing joy and comfort to pediatric cancer patients and their families.
  • Through their non-profit arm, Fresh Coat Cares, Matt Boden , owner of Fresh Coat Painters of Tampa , is leading the charge to provide pro bono painting projects for children undergoing cancer treatment.
  • "I am deeply honored to be able to give back to the pediatric cancer community," says Matt Boden.
  • Christopher Geib, Chief Development Officer of the National Pediatric Cancer Foundation , expressed gratitude for the partnership, stating, "We are thrilled to collaborate with Fresh Coat Painters of Tampa and Fresh Coat Cares in this meaningful endeavor.

Proposed Changes to BenevolentAI’s Board Composition

Retrieved on: 
Lundi, avril 15, 2024
Technology, Research, Finance, Health Technology, Professional Services, Biotechnology, Health, Science, Artificial Intelligence, Annual general meeting, CFO, Cure, Investment, AI, Neo-noir, Partnership, Business, Growth, Corporate development, GI Partners, BAI, Intellectual property, Drug discovery, LifeArc, AIM, Trust, Amphisbaena, Nomination, Therapy, Euronext Amsterdam, Abcam, P74, Research and development, Trustee, Artificial intelligence, Observation, Chairperson, Digital, Recipharm, Partner, Government, Sale, The Carlyle Group, Business development, Accel-KKR, Senior, Acquisition, F2G, Risk, Audit, AGM, Oxford Nanopore Technologies, Management

Dr. Joerg Moeller, Chief Executive Officer, Jean Raby, Senior Independent Director, Prof. Sir Nigel Shadbolt and Dr. John Orloff, both Non-Executive Directors, will all continue in their respective positions on the Board of BenevolentAI.

Key Points: 
  • Dr. Joerg Moeller, Chief Executive Officer, Jean Raby, Senior Independent Director, Prof. Sir Nigel Shadbolt and Dr. John Orloff, both Non-Executive Directors, will all continue in their respective positions on the Board of BenevolentAI.
  • Subject to their appointment at the AGM, it is proposed that Mr. Allen acts as Chair and Mr. Mulvany acts as Deputy Chair of the Board.
  • Together with the rest of the Board, they will support Chief Executive Dr. Jeorg Moeller and his team on implementing the Company’s strategy.
  • He has extensive Board experience in public and private companies and is currently Chairman of Bioventix plc, where he was appointed in 2004 and a Board Trustee of LifeArc, a leading UK medical research charity.

Susan G. Komen® Minnesota Race for the Cure Raises Funds for Breast Cancer Patient Care Services

Retrieved on: 
Jeudi, avril 11, 2024
Women, Philanthropy, Health, Fund Raising, Consumer, General Health, Other Philanthropy, Foundation, Oncology, Federation, Cure, Health equity, Patient, Research, Breast, Breast cancer, Dietary supplement

Susan G. Komen ®, the world’s leading breast cancer organization, will hold the annual Susan G. Komen Minnesota Race for the Cure on Saturday, May 11, 2024, at Viking Lakes in Eagan, Minnesota.

Key Points: 
  • Susan G. Komen ®, the world’s leading breast cancer organization, will hold the annual Susan G. Komen Minnesota Race for the Cure on Saturday, May 11, 2024, at Viking Lakes in Eagan, Minnesota.
  • This signature event enables Komen to raise critical funds that provide direct support to breast cancer patients, fund groundbreaking research, empower health equity initiatives nationwide, and advocate for change at both the state and federal government levels.
  • “We are excited to host the annual Minnesota Race for the Cure this year and provide a community for all individuals impacted by breast cancer.
  • Funds raised from this annual event fund critical research to improve outcomes for all and bring us closer to finding the cures for all breast cancers,” said Alicia Gordon Macalus, executive director, Minnesota, Susan G. Komen.

The Foundation for Women's Cancer Named "Partner-of-Choice" by The Institute for Surgical Excellence Receiving $155,555 to Drive Change in Women's Cancer

Retrieved on: 
Jeudi, avril 18, 2024
Education, SGO, Society, Cancer, Cure, Learning, Social media, Machine learning, Surgeon, Gynecologic Oncology (journal), Research, Artificial intelligence, Ginger, Celebration, Patient, Society of Gynecologic Oncology, Physician, Movement, Oncology nursing, FWC, Student, FACOG, Knowledge

CHICAGO, April 18, 2024 /PRNewswire-PRWeb/ -- The Foundation for Women's Cancer (FWC), the official foundation of the Society of Gynecologic Oncology (SGO), launched its signature annual fundraising campaign, Move4Her, last month in San Diego in conjunction with the Institute for Surgical Excellence (ISE) Celebration of Champions Day (March 14), FWC Patient & Advocate Education Forum (March 15), and SGO Annual Meeting on Women's Cancer (March 16-18).

Key Points: 
  • "It was spectacular to bring so many people together for a common cause, to share knowledge and build community.
  • The resulting donation from the ISE to the FWC will help meet critical needs in education, awareness, and grants to further research in women's cancer."
  • "It was spectacular to bring so many people together for a common cause, to share knowledge and build community.
  • "There are so many exciting medical breakthroughs happening that will improve the lives of people faced with a cancer diagnosis.

The Inner Circle acknowledges Leslie M. Boyden as a Top Pinnacle Professional

Retrieved on: 
Mardi, avril 9, 2024
Alzheimer's disease, FOX, Small business, Cure, Retirement, CBS MoneyWatch, Radio, Animal, News, CBS News, Insurance, CBS, Lions Clubs International, Growth, Information technology, Lion, Financial planner, Society, Television, Nationwide, Consultant, Inner circle, Philosophy, Organization, Knowledge, American Heart Association, Management

PORT REPUBLIC, Md., April 9, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Leslie M. Boyden is acknowledged as a Top Pinnacle Professional for her contributions as a Renowned Financial Expert.

Key Points: 
  • PORT REPUBLIC, Md., April 9, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Leslie M. Boyden is acknowledged as a Top Pinnacle Professional for her contributions as a Renowned Financial Expert.
  • Mrs. Boyden, a distinguished figure in the financial services industry with over 15 years of experience, specializes in retirement planning.
  • Mrs. Boyden's expertise is not limited to her professional life; she is also an accomplished author, having penned "Retirement Conquered" in 2022.
  • Mrs. Boyden acknowledges her husband, Carl Boyden, and father, Eric Coon, for their unwavering support.

NOVAGOLD Reports First Quarter 2024 Financial Results

Retrieved on: 
Mercredi, avril 3, 2024
Iron Dog, Learning, ANCSA, Environmental protection, Salmon, Bank statement, Investment, Nature, SCAC, Water quality, K300, Hydrology, Science, Partnership, Alaska Natives, Education, EDGAR, Calista Corporation, TKC, Feasibility study, Social responsibility, Alaska Supreme Court, Supreme court, Safety, Federal, State, Weather, Judiciary of Alaska, Sport, Internet, Sleep, Human, University, Certification, TSX, Work, Cure, Mining, Health, Earthjustice, ADNR, Barrick Gold, Form 10-Q, Gold, Bethel Regional High School, Groundwater, Fishery, Music, Alaska Native corporation

VANCOUVER, British Columbia, April 03, 2024 (GLOBE NEWSWIRE) -- NOVAGOLD RESOURCES INC. (“NOVAGOLD” or “the Company” (NYSE American, TSX: NG) today released its 2024 first quarter financial results and an update on its Tier One1 gold development project, Donlin Gold, which NOVAGOLD owns equally with Barrick Gold Corporation (“Barrick”).

Key Points: 
  • VANCOUVER, British Columbia, April 03, 2024 (GLOBE NEWSWIRE) -- NOVAGOLD RESOURCES INC. (“NOVAGOLD” or “the Company” (NYSE American, TSX: NG) today released its 2024 first quarter financial results and an update on its Tier One1 gold development project, Donlin Gold, which NOVAGOLD owns equally with Barrick Gold Corporation (“Barrick”).
  • Details of the financial results for the quarter ended February 29, 2024, are presented in the consolidated financial statements and quarterly report filed on Form 10-Q on April 3, 2024, that is available on the Company’s website at www.novagold.com, on SEDAR+ at www.sedarplus.ca, and on EDGAR at www.sec.gov.
  • During the first quarter of 2024, with the support from the owners and the Donlin Gold LLC Board, numerous important activities were conducted.
  • In the first quarter of 2024, Donlin Gold finalized another Shared Values Statement, bringing the total count to 16.

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

Retrieved on: 
Mercredi, mars 27, 2024
Research, NCI, AON, Development, Sarcoma, Disease, Neuroblastoma, Shareholder, Patient, CNS, Fast Track, Cash, SBIR, NDA, Syndrome, Cancer, MRR, CLR, BNS, University, Head, External beam radiotherapy, Cure, Wisconsin Alumni Research Foundation, WAM, HERE, Completeness, Safety, Tat, Intellectual property, Patent, PLE, WARF, Symantec Endpoint Protection, Tranche, UW, Pharmaceutical industry

FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.
  • Net cash used in operating activities during the twelve months ended December 31, 2023, was approximately $32.4 million.
  • General and Administrative Expense: G&A expense for the year ended December 31, 2023, was $10.7 million, compared to $9.6 million for the year ended December 31, 2022.
  • Cellectar management will host a conference call for investors today, March 14, 2024, beginning at 8:30 am Eastern Time to discuss these results and answer questions.